<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00164190</url>
  </required_header>
  <id_info>
    <org_study_id>MCT-69798</org_study_id>
    <secondary_id>FRN:69798</secondary_id>
    <nct_id>NCT00164190</nct_id>
  </id_info>
  <brief_title>Routine Angioplasty and Stenting After Fibrinolysis for Acute Myocardial Infarction</brief_title>
  <official_title>Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction- The TRANSFER-AMI Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Heart Research Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guidant Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Heart Research Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      In Canada, most patients with acute myocardial infarction (AMI) present to hospitals without&#xD;
      cardiac catheterization facilities. Thrombolytic therapy remains the standard-of-care in&#xD;
      these centres. However, thrombolytic therapy achieves normal coronary flow and myocardial&#xD;
      perfusion in less than 50% of patients, and is associated with reocclusion, reinfarction, and&#xD;
      recurrent ischemia. Primary angioplasty results in more complete reperfusion and lower rates&#xD;
      of reocclusion, reinfarction and recurrent ischemia, but is not available in most centres.&#xD;
      Although patients can be transferred for primary angioplasty, long transport times are&#xD;
      associated with worse outcomes. An alternative strategy, described as facilitated&#xD;
      angioplasty, involves administration of thrombolytic therapy at the community hospital&#xD;
      followed by immediate transport for angioplasty. This approach achieves the benefits of&#xD;
      primary angioplasty without delaying treatment. A well-conducted, prospective, randomized&#xD;
      trial is needed to compare this strategy of facilitated angioplasty with standard&#xD;
      thrombolytic therapy.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      To evaluate the safety, feasibility, and efficacy of routine transfer of patients with AMI to&#xD;
      an angioplasty centre immediately after thrombolysis for coronary angiography and&#xD;
      percutaneous coronary intervention (PCI).&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      A strategy of routine transfer of patients with AMI to an angioplasty centre immediately&#xD;
      after thrombolysis for coronary angiography and percutaneous intervention is associated with&#xD;
      a significantly lower incidence of the composite of death, reinfarction, recurrent ischemia,&#xD;
      heart failure, and shock at 30 days compared with the conventional strategy of thrombolysis&#xD;
      with transfer reserved for failed reperfusion and/or development of shock.&#xD;
&#xD;
      Research Plan:&#xD;
&#xD;
      Patients with ST-elevation myocardial infarction and high-risk characteristics presenting to&#xD;
      community hospitals without cardiac catheterization facilities will receive thrombolysis with&#xD;
      tenecteplase and heparin (unfractionated or low molecular weight heparin) and will then be&#xD;
      randomized to one of two strategies: facilitated PCI or standard treatment (thrombolysis with&#xD;
      provisional rescue PCI). In the facilitated PCI group, patients will be transferred&#xD;
      immediately to an angioplasty centre for urgent cardiac catheterization, and PCI if&#xD;
      appropriate. In the standard treatment group, patients will only undergo urgent angiography&#xD;
      for evidence of failed reperfusion and/or development of cardiogenic shock. The primary&#xD;
      endpoint will be the composite of death, reinfarction, recurrent ischemia, heart failure, and&#xD;
      shock at 30 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with ST-elevation myocardial infarction and high-risk characteristics presenting to&#xD;
      community hospitals without cardiac catheterization facilities will receive thrombolysis with&#xD;
      tenecteplase and heparin (unfractionated or low molecular weight heparin) and will then be&#xD;
      randomized to one of two strategies: facilitated percutaneous coronary intervention (PCI) or&#xD;
      standard treatment (thrombolysis with provisional rescue PCI). In the facilitated PCI group,&#xD;
      patients will be transferred immediately to an angioplasty centre for urgent cardiac&#xD;
      catheterization, and PCI if appropriate within 6 hours of thrombolysis. In the standard&#xD;
      treatment group, patients will only undergo urgent angiography for evidence of failed&#xD;
      reperfusion and/or development of cardiogenic shock.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30-day composite of death (all cause)</measure>
    <time_frame>30 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reinfarction</measure>
    <time_frame>30 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrent ischemia</measure>
    <time_frame>30 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>New or worsening congestive heart failure, including readmission for heart failure</measure>
    <time_frame>30 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Development of cardiogenic shock requiring inotropic support or intra-aortic balloon pump insertion</measure>
    <time_frame>30 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of major/severe bleeding, as defined by the thrombolysis in myocardial ischemia (TIMI) and Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) bleeding classifications in the first 30 days</measure>
    <time_frame>30 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with complete (&gt; 70%) and partial (30-70%) ST-segment resolution from the qualifying electrocardiogram (ECG) to 6 hours after randomization</measure>
    <time_frame>30 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct size as assessed by QRS scoring system on the 180 minute 12-lead electrocardiogram</measure>
    <time_frame>30 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The composite of death or reinfarction at 6 months</measure>
    <time_frame>30 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The composite of death or reinfarction at 1 year</measure>
    <time_frame>30 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health costs</measure>
    <time_frame>30 day</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Myocardial Infarction</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Routine Early Percutaneous Coronary Intervention after Thrombolysis</intervention_name>
    <description>early or delayed PCI</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Patients &gt;= 18 years old who present within 12 hours of symptom onset with more than 30&#xD;
        minutes of continuous symptoms of an acute myocardial infarction to a centre that does not&#xD;
        perform primary PCI, with either:&#xD;
&#xD;
          -  &gt;= 2 mm ST-segment elevation in 2 or more contiguous anterior leads&#xD;
&#xD;
          -  &gt;= 1 mm ST-segment elevation in 2 or more contiguous inferior leads with at least one&#xD;
             of the following high-risk features:&#xD;
&#xD;
               -  Systolic blood pressure &lt; 100 mm Hg&#xD;
&#xD;
               -  Heart rate &gt; 100/minute&#xD;
&#xD;
               -  Killip Class II-III&#xD;
&#xD;
               -  &gt;= 2 mm ST-segment depression in anterior leads&#xD;
&#xD;
               -  &gt;= 1 mm ST-segment elevation in right-sided lead V4 (V4R), indicative of right&#xD;
                  ventricular involvement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Left bundle branch block&#xD;
&#xD;
          2. Cardiogenic shock (Killip Class IV requiring vasopressors or inotropic support to&#xD;
             maintain a systolic blood pressure &gt; 90) prior to randomization&#xD;
&#xD;
          3. Active bleeding or known hemorrhagic diathesis&#xD;
&#xD;
          4. Availability of primary PCI with door-to-balloon time â‰¤ 60 minutes&#xD;
&#xD;
          5. Time from thrombolysis to initiation of consent process &gt; 30 minutes&#xD;
&#xD;
          6. Use of thrombolytic agent other than tenecteplase (TNK) for index event&#xD;
&#xD;
          7. Major surgery, biopsy of parenchymal organ, or significant trauma in the past 6 weeks&#xD;
&#xD;
          8. Systolic blood pressure &gt; 200 mm Hg or diastolic &gt; 110 mm Hg after arrival to the&#xD;
             hospital and before enrollment&#xD;
&#xD;
          9. Concomitant use of oral anticoagulants (e.g. warfarin) with International Normalized&#xD;
             Ratio (INR) of &gt; 2&#xD;
&#xD;
         10. Recent non-compressible vascular puncture&#xD;
&#xD;
         11. History of central nervous system structural damage (e.g. aneurysm, neoplasm,&#xD;
             arteriovenous malformation, stroke) at any time, or transient ischemic attack within&#xD;
             the last year&#xD;
&#xD;
         12. History of heparin-induced thrombocytopenia&#xD;
&#xD;
         13. Documented allergy to aspirin&#xD;
&#xD;
         14. Participation in other clinical research studies involving experimental therapies&#xD;
             including drugs or devices within 7 days of enrollment or prior participation in this&#xD;
             study&#xD;
&#xD;
         15. Inability to cooperate with the protocol or undergo cardiac catheterization&#xD;
&#xD;
         16. Other serious illness (e.g. active cancer, significant hepatic disease)&#xD;
&#xD;
         17. Serum creatinine &gt; 140 umol/L&#xD;
&#xD;
         18. Percutaneous coronary intervention within one month&#xD;
&#xD;
         19. Previous bypass surgery&#xD;
&#xD;
         20. Pregnancy&#xD;
&#xD;
         21. Use of enoxaparin (or other low molecular weight heparin) in last 12 hours in patient&#xD;
             &gt; 75 years of age&#xD;
&#xD;
         22. Inferior ST-elevation myocardial infarction with none of the 5 high-risk features&#xD;
             listed in the inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Warren J. Cantor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Caribbean Health Research Council</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southlake Regional Health Centre</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2R2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>October 14, 2010</last_update_submitted>
  <last_update_submitted_qc>October 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Warren Cantor</name_title>
    <organization>Canadian Heart Research Centre</organization>
  </responsible_party>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Thrombolysis</keyword>
  <keyword>Angioplasty</keyword>
  <keyword>ST Elevation Myocardial Infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

